These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

766 related items for PubMed ID: 8567767

  • 1. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC, Grimbizis G, Pournaropoulos F, Bontis J, Lagos S, Spanos E, Mantalenakis S.
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [Abstract] [Full Text] [Related]

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S.
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [Abstract] [Full Text] [Related]

  • 3. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY, Guu HF, Yi YC, Chen MJ, Ho ES.
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [Abstract] [Full Text] [Related]

  • 4. [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome].
    Geng X, Ou X, Liao Y, Tan W, Wang S, Quan S.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):857-60. PubMed ID: 23803197
    [Abstract] [Full Text] [Related]

  • 5. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R, Buckler HM, Matson P, Lieberman B, Burger HG, Hilton B, Horne G, Dyson M, Robertson WR.
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [Abstract] [Full Text] [Related]

  • 6. Polycystic ovary syndrome: low-dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients.
    Dale PO, Tanbo T, Haug E, Abyholm T.
    Hum Reprod; 1992 Sep; 7(8):1085-9. PubMed ID: 1400931
    [Abstract] [Full Text] [Related]

  • 7. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology.
    Teissier MP, Chable H, Paulhac S, Aubard Y.
    Hum Reprod; 1999 Sep; 14(9):2236-41. PubMed ID: 10469686
    [Abstract] [Full Text] [Related]

  • 8. Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation.
    Cahill DJ, Prosser CJ, Wardle PG, Ford WC, Hull MG.
    Br J Obstet Gynaecol; 1994 Nov; 101(11):999-1002. PubMed ID: 7999732
    [Abstract] [Full Text] [Related]

  • 9. Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease.
    van Weissenbruch MM, Schoemaker HC, Drexhage HA, Schoemaker J.
    Hum Reprod; 1993 Jun; 8(6):813-21. PubMed ID: 8345068
    [Abstract] [Full Text] [Related]

  • 10. Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome.
    Farhi J, Jacobs HS.
    Fertil Steril; 1997 Mar; 67(3):459-62. PubMed ID: 9091330
    [Abstract] [Full Text] [Related]

  • 11. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T, Ishimaru T, Fujishita A, Kawano M, Yamabe T.
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [Abstract] [Full Text] [Related]

  • 12. Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment.
    Wiser A, Shehata F, Holzer H, Hyman JH, Shalom-Paz E, Son WY, Tulandi T.
    J Reprod Med; 2013 Aug; 58(5-6):219-23. PubMed ID: 23763006
    [Abstract] [Full Text] [Related]

  • 13. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R, Conway GS, Engmann L, Bekir JS, Jacobs HS.
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [Abstract] [Full Text] [Related]

  • 14. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation.
    Ganor-Paz Y, Friedler-Mashiach Y, Ghetler Y, Hershko-Klement A, Berkovitz A, Gonen O, Shulman A, Wiser A.
    J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707
    [Abstract] [Full Text] [Related]

  • 15. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH.
    Fleming R, Rehka P, Deshpande N, Jamieson ME, Yates RW, Lyall H.
    Hum Reprod; 2000 Jul; 15(7):1440-5. PubMed ID: 10875848
    [Abstract] [Full Text] [Related]

  • 16. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation.
    Anderson RA, Groome NP, Baird DT.
    Clin Endocrinol (Oxf); 1998 May; 48(5):577-84. PubMed ID: 9666869
    [Abstract] [Full Text] [Related]

  • 17. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

  • 18. [Effect of luteinizing hormone vs follicular stimulating hormone ratio on anti-Müllerian hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].
    Li Y, Wei LN, Xiong YL, Liang XY.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):567-70. PubMed ID: 21029609
    [Abstract] [Full Text] [Related]

  • 19. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?
    Orvieto R, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R.
    Gynecol Endocrinol; 2012 Jun; 28(6):422-4. PubMed ID: 22578028
    [Abstract] [Full Text] [Related]

  • 20. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C, Rahman A, Sbracia M, Pappalardo S, Mohamed EI, Linder R, Nardo LG.
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.